Research programme: human cytomegalovirus inhibitors - GPC Biotech/4SC

Drug Profile

Research programme: human cytomegalovirus inhibitors - GPC Biotech/4SC

Alternative Names: HCMV kinase inhibitors - GPC Biotech/4SC

Latest Information Update: 23 Jan 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC; GPC Biotech AG
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 26 Apr 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in Germany (unspecified route)
  • 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
  • 03 Sep 2002 Preclinical trials in Cytomegalovirus infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top